title: Plasma fatty acids and lipid hydroperoxides increase after antibiotic therapy in cystic fibrosis.
abstract: The present authors investigated whether cystic fibrosis is linked to a defect in fatty acids and assessed the impact of the main patients' characteristics on the levels of several fatty acids, mostly during respiratory exacerbation and after antibiotic therapy. Fatty acid phospholipid and cholesteryl ester levels were measured in stable-state patients and controls. No differences were found concerning either the fractions of palmitic and oleic acids or the cholesteryl esters of alpha-linolenic and arachidonic acids. However, phospholipids of alpha-linolenic and arachidonic acids, as well as cholesteryl esters and phospholipids of stearic and linoleic acids, were lower in patients than in controls, but fractions of dihomo-gamma-linolenic, docosatetraenoic, docosapentaenoic, palmitoleic and eicosatrienoic acids were higher. Fatty acid levels, oxidative stress markers, nutrients, body mass index and forced expiratory volume in one second (FEV(1)) were measured in patients before and after antibiotic courses for bronchial exacerbation. After adjustments, palmitic, stearic, alpha-linolenic, linoleic, arachidonic, palmitoleic and oleic acids generally decreased during exacerbation but almost all increased after antibiotic courses. Nearly all fractions increased along with FEV(1) and a positive relationship linked fatty acids to lipid hydroperoxides. There was no general drop in fatty acids. Patients' fatty acid profiles depended on the pulmonary function and the inflammation state.
authors.affiliation: Dept of Internal Medicine and Cystic Fibrosis, Adult Centre, Université Claude Bernard and Hospices Civils de Lyon, Lyon Cedex, France. isabelle.durieu@chu-lyon.fr
authors.forename: I
authors.initials: I
authors.lastname: Durieu
authors.forename: F
authors.initials: F
authors.lastname: Abbas-Chorfa
authors.forename: J
authors.initials: J
authors.lastname: Drai
authors.forename: J
authors.initials: J
authors.lastname: Iwaz
authors.forename: J-P
authors.initials: JP
authors.lastname: Steghens
authors.forename: M
authors.initials: M
authors.lastname: Puget
authors.forename: R
authors.initials: R
authors.lastname: Ecochard
authors.forename: G
authors.initials: G
authors.lastname: Bellon
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000097:blood* / Q000188:drug therapy*; D005227:Fatty Acids / Q000097:blood*; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D007223:Infant; D008054:Lipid Peroxides / Q000097:blood*; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D011446:Prospective Studies; D012044:Regression Analysis
chemical_list: D000900:Anti-Bacterial Agents; D005227:Fatty Acids; D008054:Lipid Peroxides